Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Concord Drugs Ltd. Share Price
Day's Range
Day's Range
Low
₹
High
₹
Price Summary
| Previous Close | ₹73.40 |
|---|---|
| Day's Range | ₹71.00 - ₹73.75 |
| Open | ₹71.00 |
| 52 Week Range | ₹49.00 - ₹92.52 |
| Volume | 1,807 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 1.33 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 89.54 |
| TTM EPS (₹) | 0.80 |
| P/E Ratio | 92.45 |
| Book Value(₹) | 1.95 |
| PAT Margin (%) | 0.74 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 5.19 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 79.69 | 369.46 |
| Expenses | N/A | N/A |
| PBT | 0.21 | 6.41 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 0.08 | 2.96 |
About Concord Drugs Ltd.
| Founded | 1995 |
|---|---|
| Managing Director | S Nagi Reddy |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,67,630.39 | 1,944.00 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 2,21,666.26 | 8,291.55 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,90,107.85 | 4,965.00 | 3,480.60 - 3,480.60 |
| Apollo Hospitals Enterprise Ltd. | 1,28,112.13 | 8,812.90 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,17,138.71 | 1,475.00 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,10,822.68 | 1,106.25 | 835.50 - 835.50 |
| Lupin Ltd. | 1,09,096.25 | 2,395.00 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 1,05,113.53 | 1,075.00 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 1,01,266.61 | 2,430.90 | 1,909.70 - 1,909.70 |
| Laurus Labs Ltd. | 99,563.33 | 1,836.00 | 810.05 - 810.05 |
No Records Found
Latest News
Deccan Health Care informs about board meeting
Suven Life Sciences informs about board meeting
Pursuant to the provisions of Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Suven Life Sciences has informed that the Board of Directors of the Company, at its meeting held today, August 6, 2026, has considered and approved Un-Audited Financial Results (Standalone and Consolidated) along with review reports of the Statutory Auditors for the quarter ended 30th June, 2026. The company has enclosed the following documents:- 1. The Un-Audited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2026 enclosed as Annexure 1, 2. Limited Review Reports of Statutory Auditors of the Company enclosed as Annexure 2, 3. News Release of the Company enclosed as Annexure 3. Update on patents are available at: https://www.suven.com/Patentupdates.aspx. The Board Meeting commenced at 11:30 AM (IST) and concluded at 12:30 PM (IST).
The above information is a part of company’s filings submitted to BSE.
Biocon informs about earnings call
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Biocon has informed that it enclosed the presentation with respect to Q1 FY27 Earnings Call to be conducted on August 06, 2026. The above information will also be available on the website of the Company at www.biocon.com.
The above information is a part of company’s filings submitted to BSE.
Shilpa Medicare - Quaterly Results
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202606 | 202506 | % Var | 202606 | 202506 | % Var | 202603 | 202503 | % Var | |
| Sales | 1890.40 | 934.60 | 102.27 | 1890.40 | 934.60 | 102.27 | 5970.30 | 4774.10 | 25.06 |
| Other Income | 95.60 | 130.20 | -26.57 | 95.60 | 130.20 | -26.57 | 381.40 | 696.70 | -45.26 |
| PBIDT | 655.70 | 328.60 | 99.54 | 655.70 | 328.60 | 99.54 | 1938.60 | 2058.00 | -5.80 |
| Interest | 25.30 | 22.30 | 13.45 | 25.30 | 22.30 | 13.45 | 100.40 | 58.70 | 71.04 |
| PBDT | 665.50 | 254.50 | 161.49 | 665.50 | 254.50 | 161.49 | 2032.40 | 1541.90 | 31.81 |
| Depreciation | 154.90 | 130.60 | 18.61 | 154.90 | 130.60 | 18.61 | 551.10 | 488.60 | 12.79 |
| PBT | 510.60 | 123.90 | 312.11 | 510.60 | 123.90 | 312.11 | 1481.30 | 1053.30 | 40.63 |
| TAX | -138.60 | -63.20 | 119.30 | -138.60 | -63.20 | 119.30 | 151.60 | 374.40 | -59.51 |
| Deferred Tax | -276.40 | 44.20 | -725.34 | -276.40 | 44.20 | -725.34 | 76.60 | -96.40 | -179.46 |
| PAT | 649.20 | 187.10 | 246.98 | 649.20 | 187.10 | 246.98 | 1329.70 | 678.90 | 95.86 |
| Equity | 195.60 | 97.80 | 100.00 | 195.60 | 97.80 | 100.00 | 195.60 | 97.80 | 100.00 |
| PBIDTM(%) | 34.69 | 35.16 | -1.35 | 34.69 | 35.16 | -1.35 | 32.47 | 43.11 | -24.68 |
Cohance Lifesciences - Quaterly Results
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202606 | 202506 | % Var | 202606 | 202506 | % Var | 202603 | 202503 | % Var | |
| Sales | 3598.90 | 4835.80 | -25.58 | 3598.90 | 4835.80 | -25.58 | 20305.00 | 25044.30 | -18.92 |
| Other Income | 121.60 | 131.00 | -7.18 | 121.60 | 131.00 | -7.18 | 447.30 | 648.40 | -31.01 |
| PBIDT | 386.50 | 1173.00 | -67.05 | 386.50 | 1173.00 | -67.05 | 4991.40 | 8490.50 | -41.21 |
| Interest | 21.20 | 68.00 | -68.82 | 21.20 | 68.00 | -68.82 | 224.60 | 367.00 | -38.80 |
| PBDT | 365.30 | 1024.00 | -64.33 | 365.30 | 1024.00 | -64.33 | 4472.10 | 7965.70 | -43.86 |
| Depreciation | 343.20 | 313.60 | 9.44 | 343.20 | 313.60 | 9.44 | 1335.80 | 1465.10 | -8.83 |
| PBT | 22.10 | 710.40 | -96.89 | 22.10 | 710.40 | -96.89 | 3136.30 | 6500.60 | -51.75 |
| TAX | 8.00 | 184.70 | -95.67 | 8.00 | 184.70 | -95.67 | 849.20 | 1588.80 | -46.55 |
| Deferred Tax | 8.00 | 3.20 | 150.00 | 8.00 | 3.20 | 150.00 | 68.20 | -124.30 | -154.87 |
| PAT | 14.10 | 525.70 | -97.32 | 14.10 | 525.70 | -97.32 | 2287.10 | 4911.80 | -53.44 |
| Equity | 382.60 | 382.60 | 0.00 | 382.60 | 382.60 | 0.00 | 382.60 | 254.60 | 50.27 |
| PBIDTM(%) | 10.74 | 24.26 | -55.73 | 10.74 | 24.26 | -55.73 | 24.58 | 33.90 | -27.49 |
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Concord Drugs Ltd. is ₹73.40 as of 2026-08-06.
The market capitalisation of Concord Drugs Ltd. is ₹94.46 as of 2026-08-05.
The 1-year return of Concord Drugs Ltd. is 17.54% as of 2025-08-05.
The P/E ratio of Concord Drugs Ltd. is 92.45 as of 2026-08-06.
The 52-week high and low of Concord Drugs Ltd. are ₹92.52 and ₹49.00, respectively, as of 2026-08-06.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
